tiprankstipranks
Trending News
More News >
Novanta (NOVT)
:NOVT
Advertisement

Novanta (NOVT) AI Stock Analysis

Compare
203 Followers

Top Page

NOVT

Novanta

(NASDAQ:NOVT)

Rating:67Neutral
Price Target:
$130.00
▲(8.13% Upside)
Novanta's strong financial performance and positive earnings call insights are offset by technical indicators suggesting bearish momentum and a high valuation. The company's growth prospects are promising, but current market conditions and valuation concerns present risks.
Positive Factors
Acquisitions
The acquisition of Keonn is expected to contribute significantly to Novanta's revenue and EBITDA.
Earnings
Novanta reported a solid second quarter with revenue, EBITDA, and EPS above consensus expectations.
Strategic Partnerships
Management announced a major design win with a 'leading e-commerce and warehouse robotics' company.
Negative Factors
Guidance
Novanta suspended 2025 revenue and EPS guidance due to extreme uncertainty from tariffs.
Sector Exposure
The administration’s proposed 44% cut to the NIH’s budget is considered ominous news for Novanta.
Trade Tariffs
The escalating trade war with China could also result in a greater-than-expected headwind for Novanta.

Novanta (NOVT) vs. SPDR S&P 500 ETF (SPY)

Novanta Business Overview & Revenue Model

Company DescriptionNovanta Inc. is a global provider of precision photonics and motion control solutions, serving a diverse range of industries including medical technology, industrial automation, and scientific research. The company specializes in designing and manufacturing advanced components such as lasers, optics, and motion systems that enhance the performance of equipment used in applications like surgical procedures, industrial manufacturing, and laboratory testing. Novanta's commitment to innovation and quality positions it as a key player in the rapidly evolving technology landscape.
How the Company Makes MoneyNovanta generates revenue primarily through the sale of its precision components and systems, which cater to various high-growth markets. Key revenue streams include the direct sale of products such as laser systems, optical components, and motion control solutions, as well as service agreements and support for its installed products. The company benefits from long-term relationships with major original equipment manufacturers (OEMs) and end-users, which often lead to repeat business and ongoing contracts. Additionally, Novanta invests in research and development to drive innovation, ensuring its products meet the evolving needs of its customers, thereby enhancing its competitive edge and revenue potential. Strategic partnerships with leading technology firms and participation in key industry events also contribute to its brand visibility and market penetration.

Novanta Earnings Call Summary

Earnings Call Date:Aug 05, 2025
(Q2-2025)
|
% Change Since: -3.05%|
Next Earnings Date:Nov 11, 2025
Earnings Call Sentiment Neutral
The earnings call presented a mix of positive achievements, including strong growth in new products, strategic design wins, and successful integration of the Kion acquisition. However, challenges such as declines in the Precision Medicine and Industrial markets, tariff impacts, and decreased operating cash flow were also highlighted.
Q2-2025 Updates
Positive Updates
Record New Product Revenue Growth
New product revenue grew by over 50% year-over-year, with design win activity growing more than 150% year-over-year.
Strong Customer Orders and Bookings
Customer orders grew 10% year-over-year and 20% sequentially, with a strong book-to-bill ratio of 1.02.
Advanced Surgery and Robotics and Automation Growth
Advanced Surgery business experienced 17% growth year-over-year, while Robotics and Automation business achieved nearly 16% growth.
Major Design Wins and Partnerships
Secured design wins in minimally invasive surgery and warehouse robotics, with a significant $50 million contract in warehouse robotics.
Kion Acquisition Success
The integration of Kion Technologies is on track, exceeding initial expectations and contributing significantly to growth.
Negative Updates
Decline in Precision Medicine and Industrial Markets
Precision Medicine business saw a 13% decline in sales year-over-year, while industrial equipment sales declined, particularly impacted by trade disruptions in China.
Impact of Tariffs and Trade Disruptions
Tariffs resulted in a $4 million net impact year-to-date, with ongoing challenges in Chinese customer orders due to tariff uncertainties.
Decrease in Operating Cash Flow
Operating cash flow for the second quarter decreased to $15 million from $41 million in the prior year, impacted by tax payment timing, increased inventory purchases, and the Kion acquisition.
Company Guidance
During Novanta Inc.'s second quarter 2025 earnings call, the company reported revenue of $241 million, marking a 2% increase in reported revenue and a 2% decline in organic revenue, surpassing guidance. New product revenue grew over 50% year-over-year, while customer orders rose 10% year-over-year and 20% sequentially. Adjusted gross margins held at 46% with an adjusted EBITDA margin of 22%. The company highlighted significant design win activity, with over 150% growth year-over-year. Novanta's Advanced Surgery business posted double-digit growth, and the Robotics and Automation segment showed strong demand, expecting sales to double in 2026 and again in 2027. Novanta's long-term growth strategy emphasizes markets with secular tailwinds, and the company remains focused on ramping new products to achieve $50 million in incremental new product revenue for 2025. The full-year 2025 guidance includes expected GAAP revenue of $970 million to $985 million, representing 2% to 4% growth, with an adjusted EBITDA margin goal of 23% and adjusted earnings per share guidance between $3.22 and $3.36.

Novanta Financial Statement Overview

Summary
Novanta demonstrates strong revenue growth and operational efficiency, with healthy margins and a solid balance sheet. However, the decline in free cash flow growth and slight pressure on net profit margins in the TTM indicate areas for improvement.
Income Statement
78
Positive
Novanta's income statement shows strong revenue growth over the years, with a notable TTM (Trailing-Twelve-Months) revenue growth rate of 54.5%. Gross profit margins are consistently healthy, hovering around 44-45%. However, net profit margins have slightly declined in the TTM, indicating some pressure on profitability. EBIT and EBITDA margins remain robust, reflecting efficient operational management.
Balance Sheet
72
Positive
The balance sheet reflects a moderate debt-to-equity ratio, which has improved over the years, indicating better financial leverage management. Return on equity has slightly decreased in the TTM, suggesting a need for improved profitability. The equity ratio remains stable, showing a solid capital structure.
Cash Flow
65
Positive
Cash flow analysis reveals a decline in free cash flow growth in the TTM, which could be a concern for liquidity. The operating cash flow to net income ratio is below 1, indicating potential cash flow constraints. However, the free cash flow to net income ratio remains strong, suggesting efficient cash generation relative to net income.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue956.88M949.25M881.66M860.90M706.79M590.62M
Gross Profit428.54M421.55M399.90M378.47M300.33M244.52M
EBITDA177.85M179.86M164.16M160.99M126.49M98.07M
Net Income61.36M64.09M72.88M74.05M50.33M44.52M
Balance Sheet
Total Assets1.51B1.39B1.23B1.24B1.23B865.18M
Cash, Cash Equivalents and Short-Term Investments109.91M113.99M105.05M100.11M117.39M125.05M
Total Debt513.41M471.00M404.56M489.38M493.40M255.05M
Total Liabilities709.62M642.81M552.60M663.63M706.59M388.37M
Stockholders Equity801.45M745.70M673.46M577.59M521.29M476.81M
Cash Flow
Free Cash Flow117.86M141.35M100.11M71.14M74.65M129.72M
Operating Cash Flow131.39M158.51M120.08M90.78M94.63M140.24M
Investing Cash Flow-71.55M-208.19M-19.89M-42.54M-306.70M-13.16M
Financing Cash Flow-51.82M56.94M-97.85M-60.15M204.75M-84.36M

Novanta Technical Analysis

Technical Analysis Sentiment
Negative
Last Price120.23
Price Trends
50DMA
124.58
Negative
100DMA
122.87
Negative
200DMA
138.65
Negative
Market Momentum
MACD
-2.04
Negative
RSI
48.74
Neutral
STOCH
40.83
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NOVT, the sentiment is Negative. The current price of 120.23 is below the 20-day moving average (MA) of 120.66, below the 50-day MA of 124.58, and below the 200-day MA of 138.65, indicating a bearish trend. The MACD of -2.04 indicates Negative momentum. The RSI at 48.74 is Neutral, neither overbought nor oversold. The STOCH value of 40.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NOVT.

Novanta Risk Analysis

Novanta disclosed 38 risk factors in its most recent earnings report. Novanta reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Novanta Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
77
Outperform
$7.17B59.768.10%0.74%10.14%57.53%
76
Outperform
$6.18B16.0435.63%0.24%1.16%0.98%
75
Outperform
$6.73B25.4711.12%0.87%4.47%2887.37%
74
Outperform
$3.53B22.2812.12%2.31%48.63%
69
Neutral
$4.78B41.739.01%0.17%10.65%15.22%
67
Neutral
$4.14B70.798.16%6.34%-1.57%
61
Neutral
$36.02B6.70-7.25%1.99%8.63%-7.76%
* Technology Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
NOVT
Novanta
120.23
-60.93
-33.63%
CGNX
Cognex
43.01
3.78
9.64%
ESE
Esco Technologies
187.48
66.51
54.98%
MKSI
MKS
101.10
-18.26
-15.30%
PLXS
Plexus
131.21
4.45
3.51%
VNT
Vontier
42.45
7.88
22.79%

Novanta Corporate Events

Executive/Board Changes
Novanta Announces Departure of General Counsel
Neutral
Jul 11, 2025

On July 8, 2025, Novanta Inc. announced that Michele D. Welsh would no longer serve as General Counsel and Corporate Secretary, effective July 18, 2025, or an earlier agreed date. There are no changes to the severance terms outlined in her employment agreement, ensuring continuity in her departure process.

Private Placements and Financing
Novanta Secures $1 Billion Credit Facility Agreement
Neutral
Jul 2, 2025

On June 27, 2025, Novanta Inc. and its subsidiaries entered into a Fourth Amended and Restated Credit Agreement with several financial institutions, including Bank of America and JP Morgan Chase, to establish a $1.0 billion credit facility. This new agreement replaces the previous credit agreement scheduled to mature in March 2027 and includes a €65.31 million euro-denominated term loan, a $75.0 million U.S. dollar-denominated term loan, and an $850.0 million revolving credit facility, all maturing in June 2030. The agreement allows for an additional $350.0 million increase in commitments under certain conditions and includes various financial covenants and obligations, such as maintaining specific leverage ratios and asset security.

Business Operations and Strategy
Novanta Announces Restructuring Plan to Streamline Operations
Neutral
Jun 9, 2025

On June 3, 2025, Novanta Inc. announced a restructuring plan aimed at streamlining operations and aligning with long-term goals. The plan includes regionalizing manufacturing, closing certain sites, and implementing cost-saving strategies, with an estimated $20 million to $25 million in pre-tax charges and anticipated annual savings of $20 million once completed. The restructuring is expected to be substantially completed within 18 months, although actual results may vary due to various risks and uncertainties.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 19, 2025